Mucosal immunopathogenesis of Francisella tularensis

Annals of the New York Academy of Sciences

Volumn 1105, Issue , 2007, Pages 266-283

  Metzger, Dennis W ^a   Bakshi, Chandra Shekhar ^a   Kirimanjeswara, Girish ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Adaptive immunity; Antibody; Francisella; IFN ; Innate immunity; Intranasal immunization; Lung; Mouse

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; BACTERIAL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; LIVE VACCINE; TULAREMIA VACCINE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

BACTERIAL INFECTION; BACTERIAL STRAIN; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; FRANCISELLA TULARENSIS; HUMAN; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNITY; IMMUNOPATHOGENESIS; LUNG INFECTION; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; REVIEW; TH1 CELL; TULAREMIA; VACCINATION; ANIMAL; IMMUNOLOGY; INNATE IMMUNITY; LUNG DISEASE; MICROBIOLOGY; PATHOGENICITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RESPIRATORY TRACT MUCOSA;

FRANCISELLA; FRANCISELLA TULARENSIS;

ANIMALS; BACTERIAL VACCINES; CYTOKINES; FRANCISELLA TULARENSIS; HUMANS; IMMUNITY, NATURAL; LUNG DISEASES; RESPIRATORY MUCOSA; TULAREMIA;

EID: 34548486031     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1409.007     Document Type: Review

References (40)

1. KUOLEE, R., X. ZHAO, J. AUSTIN, et al. 2007. Mouse model of oral infection with virulent type A Francisella tularensis. Infect. Immun. 75: 1651-1660.
2. CHEN, W., R. KUOLEE, H. SHEN & J.W. CONLAN. 2004. Susceptibility of immunodeficient mice to aerosol and systemic infection with virulent strains of Francisella tularensis. Microb. Pathog. 36: 311-318.
3. BALAGOPAL, A., A.S. MACFARLANE, N. MOHAPATRA, et al. 2006. Characterization of the receptor-ligand pathways important for entry and survival of Francisella tularensis in human macrophages. Infect. Immun. 74: 5114-5125.
4. BEN, N.A., J. HAITHCOAT, J.E. MASTERSON, et al. 2006. Critical role for serum opsonins and complement receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in phagocytosis of Francisella tularensis by human dendritic cells (DC): uptake of Francisella leads to activation of immature DC and intracellular survival of the bacteria. J. Leukoc. Biol. 80: 774-786.
5. LOEGERING, D.J., J.R. DRAKE, J.A. BANAS, et al. 2006. Francisella tularensis LVS grown in macrophages has reduced ability to stimulate the secretion of inflammatory cytokines by macrophages in vitro. Microb. Pathog. 41: 218-225.
6. CHEN, W., R. KUOLEE, H. SHEN, et al. 2004. Toll-like receptor 4 (TLR4) does not confer a resistance advantage on mice against low-dose aerosol infection with virulent type A Francisella tularensis. Microb. Pathog. 37: 185-191.
7. MALIK, M., C.S. BAKSHI, B. SAHAY, et al. 2006. Toll-like receptor 2 is required for control of pulmonary infection with Francisella tularensis. Infect. Immun. 74: 3657-3662.
8. KATZ, J., P. ZHANG, M. MARTIN, et al. 2006. Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS. Infect. Immun. 74: 2809-2816.
9. BOSIO, C.M. & S.W. DOW. 2005. Francisella tularensis induces aberrant activation of pulmonary dendritic cells. J. Immunol 175: 6792-6801.
10. BEN, N.A., J. HAITHCOAT, J.E. MASTERSON, et al. 2006. Critical role for serum opsonins and complement receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in phagocytosis of Francisella tularensis by human dendritic cells (DC): uptake of Francisella leads to activation of immature DC and intracellular survival of the bacteria. J. Leukoc. Biol. 80: 774-786.
11. TELEPNEV, M., I. GOLOVLIOV & A. SJOSTEDT. 2005. Francisella tularensis LVS initially activates but subsequently down-regulates intracellular signaling and cytokine secretion in mouse monocytic and human peripheral blood mononuclear cells. Microb. Pathog. 38: 239-247.
12. MCCAFFREY, R.L. & L.A. ALLEN. 2006. Francisella tularensis LVS evades killing by human neutrophils via inhibition of the respiratory burst and phagosome escape. J. Leukoc. Biol. 80: 1224-1230.
13. SJOSTEDT, A., J.W. CONLAN & R.J. NORTH. 1994. Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection. Infect. Immun. 62: 2779-2783.
14. CONLAN, J.W., R. KUOLEE, H. SHEN & A. WEBB. 2002. Different host defences are required to protect mice from primary systemic vs pulmonary infection with the facultative intracellular bacterial pathogen, Francisella tularensis LVS. Microb. Pathog. 32: 127-134.
15. MALIK, M., C.S. BAKSHI, K. MCCABE, et al. 2007. Matrix metalloproteinase 9 activity enhances host susceptibility to pulmonary infection with type A and B strains of Francisella tularensis. J. Immunol 178: 1013-1020.
16. HALL, J.D., R.R. CRAVEN, J.R. FULLER, et al. 2007. Francisella tularensis replicates within alveolar type II epithelial cells in vitro and in vivo following inhalation. Infect. Immun. 75: 1034-1039.
17. LOPEZ, M.C., N.S. DUCKETT, S.D. BARON & D.W. METZGER. 2004. Early activation of NK cells after lung infection with the intracellular bacterium, Francisella tularensis LVS. Cell Immunol 232: 75-85.
18. GOSSELIN, E.J., D.R. GOSSELIN & S.A. LOTZ. 2005. Natural killer and CD8 T cells dominate the response by human peripheral blood mononuclear cells to inactivated Francisella tularensis live vaccine strain. Hum. Immunol 66: 1039-1049.
19. SJOSTEDT, A., R.J. NORTH & J.W. CONLAN. 1996. The requirement of tumour necrosis factor-α and interferon-γ for the expression of protective immunity to secondary murine tularaemia depends on the size of the challenge inoculum. Microbiol. 142: 1369-1374.
20. ANTHONY, L.S., E. GHADIRIAN, F.P. NESTEL & P.A. KONGSHAVN. 1989. The requirement for gamma interferon in resistance of mice to experimental tularemia. Microb. Pathog. 7: 421-428.
21. LEIBY, D.A., A.H. FORTIER, R.M. CRAWFORD, et al. 1992. In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies. Infect. Immun. 60: 84-89.
22. DUCKETT, N.S., S. OLMOS, D.M. DURRANT & D.W. METZGER. 2005. Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect. Immun. 73: 2306-2311.
23. PAMMIT, M.A., E.K. RAULIE, C.M. LAURIANO, et al. 2006. Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect. Immun. 74: 2063-2071.
24. ELKINS, K.L., A. COOPER, S.M. COLOMBINI, et al. 2002. In vivo clearance of an intracellular bacterium, Francisella tularensis LVS, is dependent on the p40 subunit of interleukin-12 (IL-12) but not on IL-12 p70. Infect. Immun. 70: 1936-1948.
25. PAMMIT, M.A., V.N. BUDHAVARAPU, E.K. RAULIE, et al. 2004. Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob. Agents Chemother. 48: 4513-4519.
26. AUERBUCH, V., D.G. BROCKSTEDT, N. MEYER-MORSE, et al. 2004. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J. Exp. Med. 200: 527-533.
27. HODGE, F.A., W.R. LEIF & M.S. SILVERMAN. 1968. Susceptibility to infection with Pasteurella tularensis and the immune response of mice exposed to continuous low dose rate of gamma radiation: NRDL-TR-68-85. Res. Dev. Tech. Rep. 1-28.
28. CHEN, W., H. SHEN, A. WEBB, et al. 2003. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine 21: 3690-3700.
29. WU, T.H., J.A. HUTT, K.A. GARRISON, et al. 2005. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A. Infect. Immun. 73: 2644-2654.
30. BAKSHI, C.S., M. MALIK, K. REGAN, et al. 2006. Superoxide dismutase B gene (sodB)-deficient mutants of Francisella tularensis demonstrate hypersensitivity to oxidative stress and attenuated virulence. J. Bacteriol. 188: 6443-6448.
31. GORDON, M., D.M. DONALDSON & G.G. WRIGHT. 1964. Immunization of mice with irradiated Pasteurella tularensis. J. Infect. Dis. 114: 435-440.
32. FULOP, M., R. MANCHEE & R. TITBALL. 1995. Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 13: 1220-1225.
33. CONLAN, J.W., H. SHEN, A. WEBB & M.B. PERRY. 2002. Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20: 3465-3471.
34. BARON, S.D., R. SINGH & D.W. METZGER. 2007. Inactivated Francisella tularensis LVS protects against respiratory tularemia by intranasal vaccination in an IgA-dependent fashion. Infect. Immun. 75: 2152-2162.
35. ARULANANDAM, B.P., M. O'TOOLE & D.W. METZGER. 1999. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J. Infect. Dis. 180: 940-949.
36. LYNCH, J.M., D.E. BRILES & D.W. METZGER. 2003. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun. 71: 4780-4788.
37. RHINEHARTJONES, T.R., A.H. FORTIER & K.L. ELKINS. 1994. Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host γ-interferon and T cells. Infect. Immun. 62: 3129-3137.
38. FULOP, M., P. MASTROENI, M. GREEN & R.W. TITBALL. 2001. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 19: 4465-4472.
39. KIRIMANJESWARA, G.S., J.M. GOLDEN, C.S. BAKSHI & D.W. METZGER. 2007. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis, J. Immunol., in press.
40. STENMARK, S. & A. SJOSTEDT. 2004. Transfer of specific antibodies results in increased expression of TNF-alpha and IL12 and recruitment of neutrophils to the site of a cutaneous Francisella tularensis infection. J. Med. Microbiol. 53: 501-504.